Nkarta Inc

$15.60 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Nkarta Inc

Nkarta, Inc. is a biopharmaceutical company that is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety and a membrane-bound form of the cytokine IL15 (mbIL-15). The Company’s co-lead product candidates are NKX101 and NKX019. NKX101 is designed to innate NK biology to detect and kill cancerous cells. The primary activating receptor for NK cells is known as NKG2D, which works through the detection of stress ligands displayed by cancerous cells. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells for understanding NK cell biology.

Stock Analysis

last close $15.6
1-mo return 16.1%
3-mo return 25.5%
avg daily vol. 494.57T
52-week high 38.49
52-week low 7.55
market cap. $721M
forward pe -
annual div. -
roe -34.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 70.4%
baraka

Subscribe now for daily local and international financial news

Subscribe